Litigation Details for ARAGON PHARMACEUTICALS, INC. v. EUGIA PHARMA SPECIALITIES LIMITED (D.N.J. 2022)

« Back to Dashboard

ARAGON PHARMACEUTICALS, INC. v. EUGIA PHARMA SPECIALITIES LIMITED (D.N.J. 2022)

Docket	2:22-cv-03186	Date Filed	2022-05-26
Court	District Court, D. New Jersey	Date Terminated	2024-05-16
Cause	15:1126 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand		Referred To	Leda Dunn Wettre
Patents	10,702,508
Link to Docket	External link to docket

Details for ARAGON PHARMACEUTICALS, INC. v. EUGIA PHARMA SPECIALITIES LIMITED (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-26				External link to document

Aragon Pharmaceuticals v. Eugia Pharma: Litigation Summary and Patent Analysis

Last updated: August 8, 2026

Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited, No. 2:22-cv-03186, was a Hatch-Waxman patent action in the U.S. District Court for the District of New Jersey involving Eugia's abbreviated new drug application for a generic version of Erleada, whose active ingredient is apalutamide. Aragon asserted patents covering apalutamide and its use in treating prostate cancer. The case was resolved through a dismissal rather than a merits judgment, leaving the commercial launch date governed by the parties' settlement terms and applicable regulatory exclusivity.

What drug and generic product were involved in Aragon v. Eugia?

The dispute involved apalutamide tablets, marketed by Janssen Biotech under the brand name Erleada. Apalutamide is an androgen-receptor inhibitor approved for prostate-cancer indications, including non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.[1]

Eugia Pharma Specialities Limited, an Aurobindo group company, filed an ANDA seeking approval to market generic apalutamide tablets. Aragon filed suit after receiving Eugia's Paragraph IV certification challenging patents associated with Erleada.

Item	Detail
Brand drug	Erleada
Active ingredient	Apalutamide
Dosage form	Oral tablets
Therapeutic class	Androgen-receptor inhibitor
NDA holder	Janssen Biotech, Inc.
Patent plaintiff	Aragon Pharmaceuticals, Inc.
Generic applicant	Eugia Pharma Specialities Limited
Court	U.S. District Court for the District of New Jersey
Case number	2:22-cv-03186
Case type	Hatch-Waxman patent infringement
Statutory basis	35 U.S.C. § 271(e)(2)

Aragon developed apalutamide and entered into a commercialization relationship with Janssen. Janssen markets Erleada, while Aragon retained patent interests or enforcement rights relevant to the asserted patents.

What patents protected Erleada in the Eugia litigation?

The litigation concerned patents directed to apalutamide and its therapeutic use. The core patent estate originated from Aragon's research into nonsteroidal androgen-receptor antagonists.

The principal U.S. patents associated with apalutamide include the following:

Patent	General subject matter	Relevance
U.S. Patent No. 8,445,507	Androgen-receptor modulators, including apalutamide	Core compound patent family
U.S. Patent No. 9,266,951	Methods of treating prostate cancer with androgen-receptor antagonists	Method-of-use protection
Related continuation patents	Compound, treatment, and formulation claims	Potential Orange Book and litigation coverage

The precise asserted patent set must be determined from the operative complaint and the patents identified in Eugia's Paragraph IV notice. Hatch-Waxman complaints typically plead infringement of each Orange Book-listed patent certified against by the ANDA applicant.

The strongest protection generally comes from claims that cover apalutamide itself or its use in an FDA-approved indication. Method-of-use claims can be narrower because a generic applicant may attempt to carve out the patented indication through a section viii statement. Compound claims are harder to design around if the ANDA product necessarily contains the claimed active ingredient.

When does apalutamide lose patent exclusivity?

Apalutamide's earliest core patent protection extends into the late 2020s, while later method-of-use and related patents may extend into the early 2030s. The effective commercial entry date depends on:

1. The patent claims asserted against Eugia.
2. Patent-term adjustment or patent-term extension.
3. Pediatric exclusivity.
4. The terms of any settlement agreement.
5. Whether other ANDA applicants receive earlier or later launch rights.

The original apalutamide compound patent family is generally the central barrier to unrestricted generic entry. Later patents may continue to create litigation risk, but they do not necessarily prevent approval if the generic applicant successfully removes or carves out the relevant indication.

Apalutamide exclusivity timeline

Milestone	Timing or status
Apalutamide development	Aragon Pharmaceuticals
FDA approval of Erleada	2018
Core patent protection	Extends into the late 2020s
Later method and related patents	May extend into the early 2030s
Generic ANDA litigation	Filed in 2022
30-month stay	Triggered by the Paragraph IV litigation, subject to statutory exceptions
Eugia case resolution	Dismissed after settlement

FDA regulatory exclusivity and patent exclusivity are separate. New chemical entity exclusivity was not the principal issue by the time Eugia filed its ANDA. The commercial constraint was the listed patent estate and the resulting 30-month stay.

What was the Paragraph IV challenge in this case?

Eugia's Paragraph IV certification asserted that one or more listed Erleada patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Aragon's lawsuit treated the ANDA filing as a technical act of infringement under 35 U.S.C. § 271(e)(2).

A Paragraph IV certification does not establish that the generic product infringes. It creates a statutory pathway for the patent holder to sue before commercial launch. The patent holder then bears the burden of proving infringement and defending the validity and enforceability of the asserted patents.

The most important legal questions would have included:

• Whether Eugia's apalutamide product fell within the asserted composition claims.
• Whether the proposed labeling induced infringement of patented treatment methods.
• Whether the asserted claims were anticipated or obvious.
• Whether written-description and enablement requirements were satisfied.
• Whether prosecution conduct supported an inequitable-conduct defense.
• Whether a section viii carve-out could avoid method-of-use liability.

What was the litigation status and outcome?

The case was resolved through dismissal rather than a reported claim-construction ruling, summary judgment decision, or trial judgment. A dismissal in this setting typically reflects a confidential Hatch-Waxman settlement.

The public docket does not establish the principal commercial term of the settlement, such as:

• The agreed generic launch date.
• Whether Eugia received an authorized-generic arrangement.
• Whether Aragon or Janssen granted a license.
• Whether the settlement included supply, royalty, or acceleration provisions.
• Whether the agreement was subject to a no-AG commitment.

A settlement dismissal therefore removes the immediate litigation dispute but does not eliminate the underlying patent risk for other ANDA applicants. Each applicant may face separate litigation based on its own Paragraph IV certifications and proposed labeling.

Did the settlement allow Eugia to launch generic apalutamide?

The public resolution of the lawsuit does not, by itself, establish that Eugia could launch immediately. A Hatch-Waxman settlement normally fixes a negotiated launch date or permits launch upon an earlier patent event, such as invalidation of the relevant patent by another court.

The key commercial scenarios are:

Scenario	Commercial effect
Launch at patent expiry	Generic entry begins after the relevant patent term ends
Negotiated early entry	Eugia launches before patent expiry under a license
Earlier entry after third-party invalidity	Settlement permits launch if another applicant defeats the patent
Authorized generic arrangement	Brand-side or affiliate supply may reduce expected generic economics
Label carve-out	Generic approval excludes a patented indication

No public merits decision in this case invalidated the apalutamide patents. Investors should therefore treat the settlement as a negotiated resolution, not as a judicial finding that the patent estate was weak.

What is the Orange Book status of Erleada?

Erleada's Orange Book listings provide the principal public map of the patent barriers relevant to ANDA applicants.[2] Listed patents can cover the active ingredient, approved methods of use, dosage forms, or other drug-product attributes.

The Orange Book does not disclose confidential settlement terms and does not guarantee that every listed patent will block every generic product. An ANDA applicant can challenge a listed patent through Paragraph IV certification, accept the patent's expiry, or submit a section viii statement for a method-of-use patent.

For apalutamide, the commercial significance of the Orange Book estate is concentrated in three areas:

1. Core chemical protection for apalutamide.
2. Treatment-method claims covering prostate-cancer populations.
3. Any formulation or dosage-related claims that read on the proposed generic tablets.

Are formulation patents a major risk for generic apalutamide?

Formulation patents may create a secondary barrier if they claim a particular tablet composition, excipient system, particle-size distribution, dissolution profile, or manufacturing process. Their value depends on whether the generic applicant must use the claimed formulation to satisfy FDA bioequivalence requirements.

A formulation patent is weaker when the generic applicant can use a materially different formulation while meeting the same release and bioequivalence specifications. It is stronger when the patent claims a necessary physical property or a formulation characteristic reflected in the reference product's regulatory specifications.

The available public record for this case does not establish that a standalone formulation patent was the dispositive issue. The core apalutamide compound and method-of-use estate remained the more important barriers.

How strong was Aragon's patent estate?

Aragon's estate had meaningful strength because it combined compound and method-of-use protection around a commercially important oncology product. The compound claims presented the largest obstacle to an ANDA applicant because a generic apalutamide product necessarily contains the same active ingredient.

The estate also had limitations:

• Core patents eventually face fixed expiration dates.
• Method-of-use patents can be addressed through labeling strategies.
• Continuation patents may have overlapping but narrower claim scope.
• Patent validity can be challenged on obviousness and written-description grounds.
• A settlement prevents the market from obtaining a judicial assessment of validity.

From a risk perspective, the estate was stronger against an immediate unrestricted generic launch than against a negotiated or indication-limited launch.

Which companies challenged Erleada patents?

Eugia was one of the generic applicants associated with an apalutamide patent challenge. Other generic companies may file separate ANDAs and Paragraph IV certifications as the market approaches the core patent expiry. Each case must be assessed independently because filing dates, asserted patents, proposed labels, and settlement terms can differ.

The competitive landscape includes:

• Janssen, the branded Erleada marketer.
• Aragon, the originating patent holder or enforcement plaintiff.
• Eugia and other ANDA applicants.
• Potential authorized-generic suppliers.
• Competing androgen-receptor inhibitors, including enzalutamide and darolutamide.

What revenue exposure did the litigation create?

Erleada is a high-value prostate-cancer product, so generic entry presents material revenue risk to Janssen and associated royalty or licensing streams. The economic impact depends on the timing and number of generic entrants.

A single first entrant may preserve substantial market value through 180-day generic exclusivity or a negotiated launch structure. Multiple entrants can accelerate price erosion after the first launch. Oncology products can experience rapid substitution, although treatment-line preferences, physician familiarity, payer controls, and differentiated indications can moderate erosion.

The settlement likely reduced near-term litigation uncertainty but did not remove long-term erosion risk after the negotiated entry date or core patent expiry.

What manufacturing and IP barriers affect generic apalutamide?

Generic manufacturers must satisfy FDA requirements for:

• Active pharmaceutical ingredient quality.
• Tablet strength and content uniformity.
• Dissolution and bioequivalence.
• Stability and packaging.
• Manufacturing-site compliance.
• Labeling consistency with the reference product.

These regulatory requirements operate separately from patent rights. A manufacturer can overcome patent risk and still face approval delays based on chemistry, manufacturing, and controls deficiencies. Conversely, FDA approval does not authorize commercial launch while enforceable patent or settlement restrictions remain in effect.

Key Takeaways

• Aragon Pharmaceuticals v. Eugia, No. 2:22-cv-03186, was a Hatch-Waxman case involving generic apalutamide, the active ingredient in Erleada.
• Aragon asserted patent rights directed to apalutamide and its use in prostate cancer.
• Eugia's Paragraph IV filing triggered statutory patent litigation and a 30-month stay.
• The case ended by dismissal after settlement, without a public merits ruling on patent validity or infringement.
• Public court records do not disclose the settlement's launch date or commercial terms.
• The core apalutamide patent estate extends into the late 2020s, with related method-of-use protection potentially reaching into the early 2030s.
• Generic-entry timing depends on the settlement, patent-term calculations, FDA approval, and any other litigation involving Erleada patents.

FAQs

Could Eugia launch generic apalutamide before the core patent expiry?

Only if the settlement granted an early license or another legal event removed the applicable patent barrier. The dismissal alone does not establish immediate launch rights.

Did the court invalidate any Erleada patent?

No reported merits decision in this action invalidated an Erleada patent. The case ended through settlement-related dismissal.

Can a generic company avoid Erleada method-of-use patents?

Potentially. An ANDA applicant may use a section viii statement and omit a patented indication if the resulting labeling and marketing conduct do not induce infringement.

Does Erleada have biosimilar competition?

No. Erleada is a small-molecule drug approved through an NDA, so competitive products are generics submitted through the ANDA pathway, not biosimilars submitted under the Biologics Price Competition and Innovation Act.

What is the principal investment risk from this litigation?

The principal risk is an earlier-than-expected generic apalutamide launch under the confidential settlement, followed by accelerated price erosion once additional generic manufacturers enter.

References

1. U.S. Food and Drug Administration. (2018). FDA approves new treatment for certain patients with prostate cancer.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited, No. 2:22-cv-03186, U.S. District Court for the District of New Jersey.
4. 21 U.S.C. § 355(j).
5. 35 U.S.C. § 271(e)(2).